Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment
Posted on: Thursday, 20 September 2007, 09:00 CDT
REDMOND, Wash. and TAMPA, Fla., Sept. 20 /PRNewswire-FirstCall/ -- The H. Lee Moffitt Cancer Center & Research Institute has selected Azyxxi(R), the Microsoft(R) unified health enterprise platform, to aid in its development of personalized cancer treatment programs. Azyxxi will be used to assimilate large quantities of diverse data, including electrocardiograms, magnetic resonance imaging scans, dynamic angiograms, ultrasound images and, ultimately, genomic information, providing a visual gateway for instant access to the information, and allowing researchers to make and prove their hypotheses within minutes instead of months.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO)
"After searching for two years, we selected Azyxxi because we believe it provides the healthcare and research context that other products in the marketplace just don't offer," said Ed Martinez, chief information officer at Moffitt. "As a product developed by physicians, Azyxxi works the way clinicians and researchers work. It provides rapid results with minimum clicks, and allows for specific queries to help analyze and visualize data."
Personalized medicine holds the promise to better align patients with treatment programs. Azyxxi will help in the mining of data that allows Moffitt to make appropriate clinical and scientific discoveries, setting the stage for relating genetic information to clinical practice.
"Azyxxi's ability to correlate information and present it in a cohesive way can help any health organization tackle almost any challenge, and this is another great example of that," said Peter Neupert, corporate vice president of the Health Solutions Group at Microsoft Corp. "We are thrilled that Moffitt recognizes Azyxxi as a tool that can help its researchers, clinicians -- and ultimately patients -- not only in the Moffitt Cancer Center but across the state of Florida."
About Moffitt Cancer Center
Located in Tampa, Florida, Moffitt Cancer Center (http://www.moffitt.org/) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer and ear, nose and throat. Moffitt's sole mission is to contribute to the prevention and cure of cancer.
About Microsoft
Founded in 1975, Microsoft is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.com
Microsoft Corp.
CONTACT: Susan McDonald, +1-503-443-7000, susanm@waggeneredstrom.com, ,or Rapid Response Team,, +1-503-443-7070, rrt@waggeneredstrom.com, both ofWaggener Edstrom Worldwide for Microsoft; or Nancy Johnson for Moffitt,+1-813-745-1478, Nancy.Johnson@moffitt.org
Web site: http://www.microsoft.com/http://www.moffitt.org/
Source: PRNewswire-FirstCall
Related Articles
- Philips' SmartArc Solution Helps Moffitt Cancer Center Reduce Radiation Treatment Time
- Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
- Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
- Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
- Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
- Moffitt Cancer Center Chief Participates in Clinical Trial Resulting in FDA Approval of New Label for Myelodysplastic Therapy VIDAZA
- Xceed Molecular Licenses Signature From Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
- Moffitt Cancer Center Takes Part in Newly Published Study in This Week's New England Journal of Medicine
- Gene Network Sciences Announces Cancer Research Collaboration With Moffitt Cancer Center
- H. Lee Moffitt Cancer Center and Inovio Biomedical to Unveil Pioneering Clinical Study Data of Plasmid DNA Delivery Using Electroporation
User Comments (0)

RSS Feeds